366 related articles for article (PubMed ID: 19878781)
1. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.
Elewski B
Clin Dermatol; 2009; 27(6 Suppl):S48-53. PubMed ID: 19878781
[TBL] [Abstract][Full Text] [Related]
2. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study.
Seckin D; Gurbuz O; Akin O
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):345-50. PubMed ID: 17309456
[TBL] [Abstract][Full Text] [Related]
3. An open-label, single-center pilot study to determine the antifungal activity of a new nonsteroidal cream (Promiseb Topical Cream) after 7 days of use in healthy volunteers.
Kircik L
Clin Dermatol; 2009; 27(6 Suppl):S44-7. PubMed ID: 19878780
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled pilot study to estimate the efficacy and tolerability of a nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis).
David E; Tanuos H; Sullivan T; Yan A; Kircik LH
J Drugs Dermatol; 2013 Apr; 12(4):448-52. PubMed ID: 23652893
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
7. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
8. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.
Ozden MG; Tekin NS; Ilter N; Ankarali H
Am J Clin Dermatol; 2010; 11(1):51-4. PubMed ID: 20000875
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
10. Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison.
Unholzer A; Varigos G; Nicholls D; Schinzel S; Nietsch KH; Ulbricht H; Korting HC
Infection; 2002 Dec; 30(6):373-6. PubMed ID: 12478328
[TBL] [Abstract][Full Text] [Related]
11. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV.
de Moraes AP; de Arruda EA; Vitoriano MA; de Moraes Filho MO; Bezerra FA; de Magalhães Holanda E; de Moraes ME
J Eur Acad Dermatol Venereol; 2007 May; 21(5):596-601. PubMed ID: 17447972
[TBL] [Abstract][Full Text] [Related]
12. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream.
Nakayama J
Eur J Dermatol; 2000; 10(7):528-32. PubMed ID: 11056423
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis.
Wannanukul S; Chiabunkana J
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S68-71. PubMed ID: 16083165
[TBL] [Abstract][Full Text] [Related]
14. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
[TBL] [Abstract][Full Text] [Related]
15. A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: an open-label trial utilizing clinical evaluation and erythema-directed digital photography.
Dall' Oglio F; Tedeschi A; Fusto CM; Lacarrubba F; Dinotta F; Micali G
G Ital Dermatol Venereol; 2017 Oct; 152(5):436-440. PubMed ID: 28121079
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk.
Rallis E; Nasiopoulou A; Kouskoukis C; Koumantaki E
Drugs Exp Clin Res; 2004; 30(5-6):191-5. PubMed ID: 15700745
[TBL] [Abstract][Full Text] [Related]
17. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2012 Oct; 11(10):1194-8. PubMed ID: 23134984
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a nonsteroidal topical cream in a guinea pig model of Malassezia furfur infection.
Nalamothu V; O'Leary AL; Kandavilli S; Fraser J; Pandya V
Clin Dermatol; 2009; 27(6 Suppl):S41-3. PubMed ID: 19878779
[TBL] [Abstract][Full Text] [Related]
19. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study.
Barikbin B; Givrad S; Yousefi M; Eskandari F
Clin Exp Dermatol; 2009 Oct; 34(7):776-80. PubMed ID: 19456797
[TBL] [Abstract][Full Text] [Related]
20. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
